beplay苹果手机能用吗研究人员领导Sean I. Savitz，医学博士，今天在《期刊》上报道干细胞that bone marrow cells used to treat ischemic stroke in an expanded Phase I trial were not only safe and feasible, but also resulted in enhanced recovery compared to a matched historical control group.

此外，据德克萨斯大学健康科学中心的团队称，使用连续扩散张量成像，首次捕获了从大脑延伸到​​脊髓的运动神经道的修复。Uthealth）。

“在典型的中风受伤中，您可以看到神经段的变性，”中风和脑血管疾病研究所以及Uthealth的McGovern医学院神经病学教授。“令我们惊讶的是，三到六个月后，我们可以看到某些患者再次增稠。我们通常不会看到如此严重的中风患者的反应水平相同，但是需要进一步的研究来确定神经区的回归是由于细胞治疗还是自然恢复的一部分。”beplay苹果手机能用吗

The team also reported that patients in the cell-treated group had a 1-point improvement in the Day 90 modified Rankin score, a 6-point scale considered the gold standard for rating stroke recovery and disability. The study patients were compared to a propensity score-based matched control group to estimate the improvement in effect size. Farhaan S. Vahidy, PhD, MBBS, MPH, associate professor of neurology and Director of Population Health at the Institute for Stroke and Cerebrovascular Disease, was first author of the paper and performed the analyses.

该试点研究始于2009年，是使用患者自己的骨髓细胞的第一项。前10名患者的结果于2011年发表在神经学纪事。

The latest paper included results from 25 patients, who received an intravenous dose of their own bone marrow cells within 72 hours after first symptoms of stroke. They were followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.

作者写道，骨髓单核细胞的再生潜力归因于影响中风恢复的各种机制，并得到了Vahidy在美国心脏协会杂志上发表的一项研究中分析的广泛的临床前研究的支持。中风，在2016年。细胞迁移到损伤部位并释放蛋白质，以减少炎症阻碍愈合过程。骨髓细胞也很容易被自体输注，从而消除了对免疫抑制药物的需求。

“According to our findings, it is feasible to perform a bone marrow harvest and then infuse the cells in a wide range of stroke patients,” Savitz said. “Well-designed randomized clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery.”

纸上的Uthealth合着者是Muhammad E. Haque，PhD。Mohammad H. Rahbar博士；Hongjian Zhu，博士；保罗·罗恩（Paul Rowan）博士；Harinder S. Juneja，医学博士；苏珊·奥尔德曼（Susan Alderman），博士，RN MSED；马里兰州医学博士Andrew D. Barreto；Arvind Bambhroliya，MBBS，MS；哈德·哈桑（Khader Hasan）博士；Jaroslaw Aronowski，医学博士，博士； and Charles S. Cox Jr., MD. James C. Grotta, MD, director of stroke research at Memorial Hermann-Texas Medical Center, was also a co-author. Researchers from Harvard Medical School, The University of Texas MD Anderson Cancer Center, The Johns Hopkins University School of Medicine, Mayo Clinic, and Baylor College of Medicine were also co-authors. Savitz, Aronowski, and Cox are also on the faculty of The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.

在过去的十年中，Savitz研究了自体干细胞和同种异体干细胞产品。beplay苹果手机能用吗他对人类骨髓干细胞产物进行了关于多赛的早期临床前研究并发表了早期的临床前研究，并刚刚在该产品的III期临床试验中招募了第一位Uthealth患者。

Savitz还是一项IIB期研究的主要研究者，该研究研究了直接注射到大脑以治疗中风障碍的干细胞疗法。审判称为双鱼座III，是一项IIB期，随机，安慰剂对照，多中心研究，总共有110名合格的缺血性中风患者，年龄在35至75岁之间，他们经历了持续性残疾，后者持续了6到12个月。有关如何注册的更多信息，请致电713-500-7085致电研究协调员Dory Parker或电子邮件beplay苹果手机能用吗dorothea.m.parker@uth.tmc.edu。